Show simple item record

dc.contributor.author Szarvas, Tibor
dc.contributor.author Sevcenco, S
dc.contributor.author Módos, Orsolya
dc.contributor.author Keresztes, Dávid
dc.contributor.author Nyirády, Péter
dc.contributor.author Csizmarik, Anita
dc.contributor.author Ristl, R
dc.contributor.author Puhr, M
dc.contributor.author Hoffmann, MJ
dc.contributor.author Niedworok, C
dc.contributor.author Hadaschik, B
dc.contributor.author Maj-Hes, A
dc.contributor.author Shariat, SF
dc.contributor.author Kramer, G
dc.date.accessioned 2019-10-03T07:42:54Z
dc.date.available 2019-10-03T07:42:54Z
dc.date.issued 2018
dc.identifier.citation journalVolume=122;journalIssueNumber=4;journalTitle=BJU INTERNATIONAL;pagerange=695-704;journalAbbreviatedTitle=BJU INT;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/7736
dc.identifier.uri doi:10.1111/bju.14415
dc.description.abstract PURPOSE: To assess the predictive value of pre-chemotherapy MMP-7, sFas, FasL serum levels as well as their changes during therapy. PATIENTS AND METHODS: Serum levels of MMP-7, Fas and FasL were determined by ELISA in 96 CRPC patients; 21 docetaxel-resistant who received one single series and 75 docetaxel-sensitive who received repeated series of docetaxel. In addition to the 96 pretreatment serum samples, 987 sera collected during chemotherapy were also analysed. RESULTS: Higher pretreatment serum MMP-7, sFas and PSA levels were significantly associated with both docetaxel-resistance (p=0.007, p=0.001, p<0.001, respectively) and shorter cancer-specific survival (p<0.001, p=0.041, p<0.001, respectively). High MMP-7 remained an independent predictor of both docetaxel resistance (HR: 2.298, 95% CI: 1.354-3.899, p=0.002) and poor cancer-specific survival (HR=2.11, 95%Cl 1.36-3.30, p=0.001) in multivariable analyses. Higher increase of MMP-7 levels in the 2(nd) treatment holiday and higher increase of PSA levels in the 1(st) and 2(nd) holidays were predictive of survival. CONCLUSIONS: Pretreatment serum MMP-7 levels may help to select CRPC patients who are likely to benefit from docetaxel chemotherapy. Furthermore, MMP-7 alone or in combination with PSA could be used for therapy monitoring. Correlative studies embedded in clinical trials are necessary to validate these biomarkers for clinical decision-making. This article is protected by copyright. All rights reserved.
dc.format.extent 695-704
dc.relation.ispartof urn:issn:1464-4096
dc.title MMP-7, sFas and FasL serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer
dc.type Journal Article
dc.date.updated 2019-09-12T18:58:52Z
dc.language.rfc3066 en
dc.rights.holder NULL
dc.identifier.mtmt 3381488
dc.identifier.wos 000445451300025
dc.identifier.pubmed 29802777
dc.contributor.department SE/AOK/K/Urológiai Klinika
dc.contributor.institution Semmelweis Egyetem


Files in this item

This file is available only from Semmelweis network

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account